Ubs Asset Management Americas Inc Ab Cellera Biologics Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 15,671,063 shares of ABCL stock, worth $31.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,671,063
Previous 4,500,000
248.25%
Holding current value
$31.7 Million
Previous $13.2 Million
165.04%
% of portfolio
0.01%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ABCL
# of Institutions
150Shares Held
132MCall Options Held
156KPut Options Held
346K-
Baker Bros. Advisors LP New York, NY27.5MShares$55.6 Million0.73% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$27 Million0.01% of portfolio
-
Baillie Gifford & CO11.2MShares$22.6 Million0.02% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$21.5 Million0.03% of portfolio
-
Ubs Group Ag5.08MShares$10.3 Million0.0% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $576M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...